Microcide Pharmaceuticals Inc., a start-up company developingproducts focusing on bacterial drug resistance, has raised $12 millionin new financing to keep operating through the end of 1995.President and CEO Jim Rurka said the money will be used to developthe company's two lead products, which are designed to target drugresistant gram-positive and gram-negative bacterial infections.Microcide, of Mountain View, Calif., expects to file its firstinvestigational new drug application with the FDA in the fourth quarterof 1995. The product, Rurka said, is an injectible antibiotic with aspectrum covering resistant gram-positive organisms, such asmethicillin-resistant staphylococci and vancomycin-resistantenterococci.The gram-negative targets are multi-drug resistant pseudonomas andpenicillin-resistant pneumococci.The $12 million in series C venture financing was raised from sevensources. The lead investor is New Enterprise Associates, of Baltimore,which contributed $2 million.The new financing increases capital investment in Microcide to a totalof $18 million. The company, formed 18 months ago, received $6million in its first infusion of capital in early 1993. _ Charles Craig
(c) 1997 American Health Consultants. All rights reserved.